Urinary Bladder Cancer Clinical Trial
Official title:
Carboplatin-gemcitabine Versus Cisplatin-gemcitabine as Neoadjuvant Chemotherapy for Treatment of Muscle Invasive Urinary Bladder Cancer: a Prospective Randomized Trial
Patients will be randomized in 1:1 ratio to two treatment groups first group will receive 3-4 cycles of neoadjuvant Carboplatin(AUC4)-Gemcitabine (treatment group) and second group will receive 3-4 cycles of neoadjuvant Cisplatin(75mg/m2 Day1)-Gemcitabine (Control group). Patients will undergo radiological assessment, full laboratory work up, and cystoscopy before undergoing either radical cystectomy or Definitive Radiotherapy concurrent with chemotherapy
Patients will be randomized in 1:1 ratio to two treatment groups first group will receive 3-4 cycles of neoadjuvant Carboplatin(AUC4)-Gemcitabine (treatment group) and second group will receive 3-4 cycles of neoadjuvant Cisplatin(75mg/m2 Day1)-Gemcitabine (Control group). Patients will undergo radiological assessment, full laboratory work up, and cystoscopy before undergoing either radical cystectomy or Definitive Radiotherapy concurrent with chemotherapy. After finishing treatment, all patients should undergo follow up every 3 months for two years then six monthly thereafter .Follow up will include History, physical examination, full laboratory works (CBC, renal function testing and liver function testing). Imaging by CT or MRI abdomen and pelvis for all patients and cystoscopy in bladder preservation protocol ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT00872495 -
Evaluation of Non-Invasive Assays for the Detection of Urothelial Cancer
|
||
| Withdrawn |
NCT05335707 -
Longitudinal Geriatric Assessment to Optimize Outcomes of Older Patients With Muscle-Invasive Bladder Cancer After Radical Cystectomy
|
||
| Completed |
NCT03998579 -
Physical Rehabilitation Among Patients Undergoing Radical Cystectomy Due to Urinary Bladder Cancer
|
N/A | |
| Not yet recruiting |
NCT04525781 -
Clinicoepidimiological Study and Clinical Outcome in Patients With Urinary Bladder Cancer
|
||
| Completed |
NCT02897765 -
A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer
|
Phase 1 | |
| Completed |
NCT06156787 -
Patterns of Urinary Bladder Cancer in Darfur, Suda
|
||
| Completed |
NCT02722538 -
Safety and Tolerability of GemRIS 225 mg in Subjects With Muscle-Invasive Bladder Cancer
|
Phase 1 | |
| Completed |
NCT02437539 -
Evaluation of a New Radiotracer (68Ga-NOTA-AE105) for Diagnosing Aggressive Cancer With Positron Emission Tomography
|
Phase 1 | |
| Completed |
NCT02139371 -
Evaluation of a New Radiotracer (64Cu-DOTA-AE105) for Diagnosing Aggressive Cancer With Positron Emission Tomography
|
Phase 0 | |
| Completed |
NCT03433924 -
An Epidemiologic Study on PD-L1 Expression Combined With Clinical Observation in the Chinese MIUBC Patients.
|
||
| Active, not recruiting |
NCT03132922 -
MAGE-A4ᶜ¹º³²T for Multi-Tumor
|
Phase 1 | |
| Completed |
NCT05946369 -
Neutrophils to Lymphocytes Ratio in Predicting the Response to BCG in Non-muscle Invasive Bladder Cancer
|
||
| Completed |
NCT00462488 -
Study of Vicinium for Treating Patients With Non-Invasive Urothelial Carcinoma In Situ
|
Phase 2 | |
| Recruiting |
NCT05621837 -
Quantifying Systemic Immunosuppression to Personalize Cancer Therapy
|
||
| Recruiting |
NCT05644041 -
Intravesical Gemcitabine in Patients With NMIBC
|
Phase 2 | |
| Completed |
NCT04635566 -
Pharmacological Enhancement for Nocturnal Incontinence in Orthotopic Bladder Substitute
|
N/A | |
| Recruiting |
NCT04861584 -
Neoadjuvant Toripalimab in Combination With Gemcitabine and Cisplatin Therapy in Local Advanced Bladder Cancer Subjects
|
Phase 2 | |
| Completed |
NCT01836978 -
Prehabilitation to Enhance Postoperative Functional Capacity Following Radical Cystectomy
|
N/A | |
| Terminated |
NCT01374789 -
PURO Panitumumab in Combination With Gemcitabine/Cisplatin in Advanced Urothelial Cancer
|
Phase 2 | |
| Recruiting |
NCT03844256 -
A Study of Mitomycin-c/ Capecitabine ChemoRadiotherapy Combined With Nivolumab Monotherapy or Ipilumimab and Nivolumab, as Bladder Sparing Curative Treatment for Muscle Invasive Bladder Cancer: the CRIMI Study
|
Phase 1/Phase 2 |